Verano: Analysts Expect Q3 Revenues Of $219.7 Million

Verano Holdings (CSE: VRNO) announced that they will be reporting their third quarter financials before the market opens on November 16th.

Analysts have a consensus C$40.38 12-month price target on the company, via a total of 7 analysts, with 2 analysts having strong buy ratings, and the other 5 having buy ratings on the company. The street high comes from Beacon Securities with a C$47 price target, and the lowest target sits at C$35.

7 analysts have revenue estimates for the third quarter. The mean between all 7 is US$219.70 million; this number has been revised slightly down from US$224.82 million at the start of May. The street high is US$224.60 million while the lowest sits at US$210 million.

7 analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 55.41%, with this number revised down from 60.72% at the start of May. Street high is a 58% estimate and the lowest sits at 53%.

Onto EBITDA estimates, there are currently 7 analysts who have third-quarter EBITDA estimates. The mean is currently US$85.64 million, with this number being revised down from US$100.17 million since the start of May. Street high sits at US$93.50 million EBITDA and the lowest being a US$63.70 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Agnico Q1 Earnings Results Overshadowed By A Sinking Gold Price

Why More People Are Starting to Feel Broke | Darrell Thomas – VRIC Media

Newmont Q1 Earnings: A Billion In Free Cash Flow… A Month!

Recommended

Altamira Gold Extends Maria Bonita Porphyry System Westward With 70.6 Metres At 0.51 g/t Hit

Antimony Resources Reports 13.9% Antimony in Latest Drill Core at Bald Hill

Related News

Antibe Therapeutics: Canaccord Upgrades Price Target To $16.50

Earlier this week, Antibe Therapeutics (TSXV: ATE) announced a strategic licensing deal with Nuance Pharm...

Thursday, February 11, 2021, 04:07:00 PM

Enthusiast Gaming: Canaccord Raises Price Target To $12

On March 22nd, Enthusiast Gaming (TSX: EGLX) released their fourth-quarter earnings and announced a partnership...

Sunday, March 28, 2021, 02:39:00 PM

Cronos: Raymond James Reiterates Price Target After PharmaCann Investment

Yesterday, Cronos Group (TSX: CRON) showed once again that the demand for U.S cannabis assets...

Tuesday, June 15, 2021, 05:50:00 PM

Silvercorp: Production Results Miss Canaccord Estimates

Last week, Silvercorp Metals Inc. (TSX: SVM) (NYSE: SVM) reported its operational results and announced...

Wednesday, July 21, 2021, 04:39:00 PM

Ayr Strategies: Canaccord Reiterates Rating Following Arizona Transaction

This week, Canaccord Genuity came out with a note reiterating their C$25 price target and...

Friday, November 6, 2020, 12:20:00 PM